Skip to main content

Peer Review reports

From: Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Original Submission
11 Feb 2018 Submitted Original manuscript
10 Aug 2018 Author responded Author comments - Nikolas von Bubnoff
Resubmission - Version 2
10 Aug 2018 Submitted Manuscript version 2
28 Oct 2018 Author responded Author comments - Nikolas von Bubnoff
Resubmission - Version 3
28 Oct 2018 Submitted Manuscript version 3
Publishing
5 Nov 2018 Editorially accepted
19 Nov 2018 Article published 10.1186/s12885-018-5045-7

You can find further information about peer review here.

Back to article page